Jaguar Health (JAGX) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

JAGX Jaguar Health

Watchlist

1.0400
+0.0449+4.51%

Close Nov 29 13:00 ET

1.0400
0.00000.00%

Post 17:02 ET

12.27MMarket Cap-287P/E (TTM)

Full Hours

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Jaguar Health Presenting December 3rd at NobleCon20 and December 5th at the Emerging Growth Conference
Jaguar HealthNov 25 00:00 ET
Jaguar Health Seeking Partner to Develop, Commercialize NP300
TipRanksNov 22 08:50 ET
Jaguar Health Family Company Napo Therapeutics Named "Best Pharmaceuticals Innovator of the Year - Europe"
Jaguar HealthNov 19 00:00 ET
Jaguar Health, Inc. (JAGX) Q3 2024 Earnings Call Transcript Summary
moomoo AINov 15 15:03 ET · Conference Call
Jaguar Health, Inc. (JAGX) Q3 2024 Earnings Call Transcript
Earnings Call TranscriptsNov 15 14:47 ET
Jaguar Health Sees Revenue Growth With New Product Launches
TipRanksNov 13 23:24 ET

Comments

MindTrader

Nov 26 03:23

When Jag When

$Jaguar Health (JAGX.US)$ When are you going to be Acquired by Roche Holdings, Inc. so that all shareholders will be very happy....When ??

Jaguar8

Nov 22 07:47

NEWS

$Jaguar Health (JAGX.US)$
Jaguar Health Seeking Partner to Develop and Commercialize NP300 Second-Generation Antisecretory Prescription Drug Candidate for Treatment of General Diarrhea in DogsJaguar Health (NASDAQ:JAGX) is seeking a partner to develop and commercialize NP300, a second-generation antisecretory drug candidate for treating general diarrhea in dogs. NP300, derived from the Croton lechleri tree, has shown safety in dogs and shares similarities with Canalevia-CA1, the company's con...

Stock_Drift

Nov 19 09:01

$Jaguar Health (JAGX.US)$

Stock_Drift

Nov 13 07:16

$Jaguar Health (JAGX.US)$

Jaguar8

Nov 13 07:04

NEWS ER

$Jaguar Health (JAGX.US)$
Positive
Net revenue increased 14% QoQ and 11% YoY to $3.1M
Mytesi prescription volume grew 10.9% QoQ
Operating loss decreased by $1.5M YoY to $7.3M
R&D expenses reduced by $2.0M YoY to $4.0M
Negative
Net loss increased by $2.1M YoY to $9.9M
Non-GAAP Recurring EBITDA loss worsened to $9.2M from $6.2M YoY
Sales and Marketing expenses increased by $0.5M YoY
G&A expenses increased by $0.3M YoY

Analyst Rating

No Data

Price Target

No Data

Heat List

Overall

No Data

JAGX Jaguar Health

Trade Overview

Capital Trend

News

Comments

Analysis

Analyst Rating

Price Target